Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pathology · Hepatocellular Carcinoma

What Does MVI Mean on an HCC Liver Pathology Report?

At a Glance

Microvascular invasion (MVI) on a liver cancer pathology report means tiny groups of cancer cells were seen inside small blood vessels near the tumor. It raises the chance of recurrence but does not prove cancer remains or has spread, so follow-up is individualized.

In this answer

3 sections

01

How MVI is Reported

02

How MVI Affects Your Care Plan

03

Post-Surgery Warning Signs

When you receive the pathology report after a liver resection (surgery to remove part of the liver) for hepatocellular carcinoma (HCC), you might see the term microvascular invasion (MVI). MVI means that a pathologist looking at your removed tissue under a microscope saw tiny clusters of liver cancer cells inside small blood vessels in or near the tumor [1]. Because these cells are microscopic, their presence usually cannot be confirmed reliably on imaging scans before surgery [2].

What MVI Does—and Does Not—Tell You
It is very important to understand that MVI is a risk factor, not a diagnosis that cancer was left behind.

  • It does not prove cancer has spread: Having MVI does not mean recurrence (the cancer coming back) is inevitable, nor does it mean cancer is currently growing elsewhere in your body [3].
  • It is not the only factor: Just as the absence of MVI does not guarantee the cancer will stay away, the presence of MVI is only one part of your overall prognosis [4].
  • It is different from macroscopic invasion: MVI is not the same as macroscopic (visible) vascular invasion, which involves larger blood vessels and is typically seen on pre-surgery scans [1][2].

How MVI is Reported

Some, but not all, pathology reports use a grading system (such as M0, M1, and M2) to describe the extent of the microscopic invasion [5]. M0 means no MVI was found. If MVI is present, the risk category depends on both the number of small blood vessels involved and how close they are to the main tumor border [5][6]. A higher category generally means more vessels are involved or they are located further from the original tumor [6][7]. Because different hospitals may use slightly different definitions, it is best to ask your doctor to explain the specific wording on your report.

Your care team will combine your MVI status with other important details—such as the size and number of tumors, surgical margins (whether the edges of the removed tissue are clear of cancer), your alpha-fetoprotein (AFP) levels, and the health of your remaining liver (such as underlying cirrhosis or hepatitis)—to estimate your personalized risk [8][9].

How MVI Affects Your Care Plan

Because MVI indicates a higher risk for recurrence—particularly within the first two years after surgery—your care team will use this information to plan your follow-up care [10][11]. When recurrences happen, they most often occur inside the liver itself, though your team will monitor your whole health [10].

  • Structured Surveillance: Regular follow-up is critical. Because recurrence can be completely silent and cause no symptoms early on, attending all your scheduled scans is essential [12]. After a liver resection, guidelines typically recommend imaging every 3 to 6 months for the first couple of years, though your doctors will individualize your exact schedule based on your complete pathology report and liver health [11][13].
  • Types of Scans: Surveillance usually involves high-quality imaging, such as a contrast-enhanced CT or MRI scan of the abdomen, and sometimes imaging of the chest [13]. The contrast material helps doctors spot new, very small tumors. (Be sure to let your team know if you have kidney issues, implanted devices, or allergies to contrast dye).
  • Blood Tests (AFP): Your team may regularly check your alpha-fetoprotein (AFP) level, a tumor marker in the blood, alongside standard liver-function tests [14]. AFP trends are most informative when interpreted with imaging [15]. It is important to know that a normal AFP does not rule out recurrence, which is why it is always used as an addition to imaging scans [16][17].
  • Additional Treatments: Currently, there is no universally standard “adjuvant” (post-surgery) treatment automatically recommended for everyone with MVI simply to prevent recurrence [18][19]. In certain situations, a multidisciplinary tumor board (a team of different specialists) might review your case to discuss risk-adapted options [18]. For selected high-risk patients, options like TACE (a procedure delivering targeted treatment to the liver) or clinical trials testing newer immunotherapy medications might be discussed [20][21]. These are individualized decisions with their own unique risks and benefits.

Post-Surgery Warning Signs

While you should never wait for symptoms to attend your regular surveillance scans, you should contact your medical team right away if you experience sudden postoperative issues such as:

  • Fever or chills
  • Worsening abdominal pain or sudden swelling
  • Yellowing of your skin or eyes (jaundice)
  • Unexplained bleeding, confusion, or shortness of breath

Common questions in this guide

What does microvascular invasion mean on an HCC pathology report?
Microvascular invasion means the pathologist saw small groups of hepatocellular carcinoma cells inside tiny blood vessels in or near the tumor. It is a risk marker for recurrence after surgery, but it does not prove that cancer remains or has spread elsewhere.
Does MVI mean my liver cancer has already spread?
No. MVI is a microscopic finding in the removed tissue and is different from visible invasion of larger blood vessels or confirmed cancer in another organ. It raises the risk of recurrence, so your team uses it with the rest of your pathology and imaging results.
What do M0, M1, and M2 mean for microvascular invasion?
M0 generally means no microvascular invasion was identified. M1 and M2 are used by some hospitals to describe increasing extent or distance of invasion, such as more vessels involved or invasion farther from the tumor. The definitions can vary, so your doctor should interpret the exact system on your report.
How will MVI change my follow-up after liver surgery?
MVI can lead your care team to plan closer monitoring for recurrence, especially during the first two years after surgery. Follow-up often includes contrast-enhanced CT or MRI of the abdomen every 3 to 6 months, sometimes chest imaging, plus AFP and liver-function blood tests; the schedule depends on your overall health and pathology.
Do I need more treatment if MVI is found?
Not automatically. There is no single post-surgery treatment recommended for every person with MVI, but a multidisciplinary liver tumor board may consider options for selected higher-risk patients, such as transarterial chemoembolization or a clinical trial of immunotherapy. The decision depends on your full pathology report, liver health, and the potential benefits and risks.
What symptoms should I report after liver resection?
Contact your medical team promptly for fever or chills, worsening abdominal pain or sudden swelling, jaundice, unexplained bleeding, confusion, or shortness of breath. Do not wait for symptoms to attend scheduled scans, because recurrence can be silent early on.
Can a normal AFP rule out recurrent HCC?
No. AFP can be normal even if HCC recurs, so doctors interpret AFP trends with imaging and liver-function tests rather than using AFP alone.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my pathology report state the extent of the microvascular invasion, and how does it combine with my tumor size and margins to affect my overall risk?
  2. 2.Based on my complete pathology report, what specific schedule of CT or MRI scans do you recommend for the next two years?
  3. 3.Was my alpha-fetoprotein (AFP) elevated before surgery, and how will we use it in my follow-up?
  4. 4.Is my case being reviewed by a multidisciplinary liver tumor board to discuss my follow-up or potential clinical trials?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

How Are AFP and PIVKA-II Used in Liver Cancer Care?How Do Doctors Choose Atezo/Bev vs STRIDE for HCC?Can You Get Liver Cancer Without Drinking Alcohol?Child-Pugh vs. ALBI for HCC: What Do They Mean for You?Can MRI Tell if a Liver Lesion Is Cancerous or Benign?When Does Liver Cancer Recur? Early vs. Late TimingWhy Is Endoscopy Needed Before Bevacizumab for HCC?What Is HCC Prognosis by Stage and Liver Function?How Is HCC Survival Improving With New Treatments?Is Liver Transplant or Resection Better for Early HCC?What Does MTM Liver Cancer Mean for Your Prognosis?How Can I Manage Scanxiety During HCC Surveillance?What Should I Ask My Hepatocellular Carcinoma Care Team?Could Symptoms Mean Liver Decompensation or Liver Cancer?What Are Liver Cancer Options After TACE Stops Working?What Does a LI-RADS 5 Score Mean for Liver Lesions?Why Is Early-Stage Liver Cancer Often Symptom-Free?

References

References (21)
  1. 1

    Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion.

    Zhang EL, Cheng Q, Huang ZY, Dong W

    Frontiers in oncology 2021; (11()):691354 doi:10.3389/fonc.2021.691354.

    PMID: 34123861
  2. 2

    Microvascular Venous Invasion in Hepatocellular Carcinoma: Why Do Recurrences Occur?

    Isik B, Gonultas F, Sahin T, Yilmaz S

    Journal of gastrointestinal cancer 2020; (51(4)):1133-1136 doi:10.1007/s12029-020-00487-9.

    PMID: 32839943
  3. 3

    Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.

    Huang C, Zhu XD, Ji Y, et al.

    BMC cancer 2017; (17(1)):58 doi:10.1186/s12885-017-3050-x.

    PMID: 28095820
  4. 4

    The impact of microvascular invasion in tumor recurrence and survival after liver resection for non-B non-C hepatocellular carcinoma: a multicenter, propensity score-matched analysis.

    Feng C, Zhang TC, Wang YT, et al.

    Surgical endoscopy 2026; (40(4)):3309-3319 doi:10.1007/s00464-026-12586-y.

    PMID: 41644643
  5. 5

    A Grading System of Microvascular Invasion for Patients with Hepatocellular Carcinoma Undergoing Liver Resection with Curative Intent: A Multicenter Study.

    Wang H, Chen JJ, Yin SY, et al.

    Journal of hepatocellular carcinoma 2024; (11()):191-206 doi:10.2147/JHC.S447731.

    PMID: 38283692
  6. 6

    Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: a multicenter retrospective cohort study from a hepatitis B virus-endemic area.

    Xu XF, Diao YK, Zeng YY, et al.

    International journal of surgery (London, England) 2023; (109(4)):841-849 doi:10.1097/JS9.0000000000000325.

    PMID: 36974673
  7. 7

    Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.

    Fuster-Anglada C, Mauro E, Ferrer-Fàbrega J, et al.

    Journal of hepatology 2024; (81(6)):995-1004 doi:10.1016/j.jhep.2024.06.018.

    PMID: 38925272
  8. 8

    An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study.

    Zhang XP, Wang K, Wei XB, et al.

    The oncologist 2019; (24(12)):e1476-e1488 doi:10.1634/theoncologist.2018-0868.

    PMID: 31138726
  9. 9

    The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study.

    Han J, Li ZL, Xing H, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2019; (21(8)):962-971 doi:10.1016/j.hpb.2018.11.005.

    PMID: 30718183
  10. 10

    Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China.

    Chen ZH, Zhang XP, Feng JK, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2022; (24(7)):1063-1073 doi:10.1016/j.hpb.2021.11.016.

    PMID: 34961677
  11. 11

    Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.

    Yao LQ, Chen ZL, Feng ZH, et al.

    Annals of surgical oncology 2022; doi:10.1245/s10434-022-11454-y.

    PMID: 35192156
  12. 12

    Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.

    Xu XF, Xing H, Han J, et al.

    JAMA surgery 2019; (154(3)):209-217 doi:10.1001/jamasurg.2018.4334.

    PMID: 30422241
  13. 13

    Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.

    Shao YY, Wang SY, Lin SM, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(4)):1051-1060 doi:10.1016/j.jfma.2020.10.031.

    PMID: 33199101
  14. 14

    Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis.

    Jiang HY, Chen J, Xia CC, et al.

    World journal of gastroenterology 2018; (24(22)):2348-2362 doi:10.3748/wjg.v24.i22.2348.

    PMID: 29904242
  15. 15

    Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

    Tzartzeva K, Obi J, Rich NE, et al.

    Gastroenterology 2018; (154(6)):1706-1718.e1 doi:10.1053/j.gastro.2018.01.064.

    PMID: 29425931
  16. 16

    Enhancing Recurrence-Free Survival Prediction in Hepatocellular Carcinoma: A Time-Updated Model Incorporating Tumor Burden and AFP Dynamics.

    Akabane M, Kawashima J, Altaf A, et al.

    Annals of surgical oncology 2025; (32(8)):5648-5656 doi:10.1245/s10434-025-17303-y.

    PMID: 40238062
  17. 17

    Prognostic significance of postoperative serological incomplete conversion of AFP and PIVKA-II after hepatic resection for hepatocellular carcinoma: a multicenter analysis of 1755 patients.

    Wang M, Qian G, Xiao H, et al.

    The oncologist 2024; (29(12)):e1723-e1733 doi:10.1093/oncolo/oyae139.

    PMID: 38907676
  18. 18

    Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.

    Chen ZH, Zhang XP, Zhou TF, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019; (45(11)):2188-2196 doi:10.1016/j.ejso.2019.06.031.

    PMID: 31256949
  19. 19

    Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study.

    Hou YC, Feng JK, Wang K, et al.

    The oncologist 2025; (30(6)) doi:10.1093/oncolo/oyaf139.

    PMID: 40504548
  20. 20

    Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.

    Wei W, Jian PE, Li SH, et al.

    Cancer communications (London, England) 2018; (38(1)):61 doi:10.1186/s40880-018-0331-y.

    PMID: 30305149
  21. 21

    Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.

    Wang K, Xiang YJ, Yu HM, et al.

    Nature medicine 2024; (30(3)):708-715 doi:10.1038/s41591-023-02786-7.

    PMID: 38242982

This page explains microvascular invasion on an HCC surgery pathology report for informational purposes only and does not constitute medical advice. Ask your liver specialist, surgeon, oncologist, or pathologist to interpret your results and follow-up plan.

Get notified when new evidence is published on Adult hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.